Maxcyte (MXCT) Total Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has reported Total Current Liabilities for 7 consecutive years, with $9.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 14.37% year-over-year to $9.9 million in Q2 2026; TTM through Jun 2026 was $9.9 million, a 14.37% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, down 9.56% from the prior year.
• Total Current Liabilities was $9.9 million for Q2 2026 at Maxcyte, down from $10.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $18.1 million in Q2 2022 and troughed at $9.9 million in Q2 2026.
• A 5-year average of $14.7 million and a median of $15.5 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 44.46% in 2022 and declined 27.08% in 2023, its largest moves.
• Over 5 years, Total Current Liabilities stood at $15.4 million in 2022, then increased by 15.74% to $17.9 million in 2023, then dropped by 11.65% to $15.8 million in 2024, then declined by 9.56% to $14.3 million in 2025, then plunged by 30.64% to $9.9 million in 2026.
• The last three Total Current Liabilities figures came in at $9.9 million (Q2 2026), $10.2 million (Q1 2026), and $14.3 million (Q4 2025), per Business Quant data.